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1. Introduction
Reactive oxygen species (ROS) are highly reactive ions and free 
radicals, including superoxide (O2–), hydroxyl radical (·OH), 
hypochlorite ion (OCl–), hydrogen peroxide (H2O2), singlet 
oxygen (1O2) and so on.[1,2] The major three sites of endogenous 
ROS generation are mitochondria, endoplasmic reticulum 
(ER), NADPH oxidase (NOX), which generate O2–.[2] In addi-
tion, superoxide dismutases (SOD) and transition metals also 
participate in the generation of H2O2 and ·OH by reacting with 
O2– and H2O2, respectively. The produced ROS play a vital role 
in physiological functions including the modulation of func-
tions of proteins, production of several hormones, regulation of 
cell signaling, mediation of inflammation, and elimination of 
pathogens.[2–5] These versatile functions of ROS are modulated 
by its amount, duration and localization.[3] In general, low levels 
Given the increasing evidence indicates that many pathological conditions 
are associated with elevated reactive oxygen species (ROS) levels, there 
have been growing research efforts focused on the development of ROS-
responsive carrier systems because of their promising potential to realize 
more specific diagnosis and effective therapy. By judicious utilization of 
ROS-responsive functional moieties, a wide range of carrier systems has been 
designed for ROS-mediated drug delivery. In this review article, insights into 
design principle and recent advances on the development of ROS-responsive 
carrier systems for drug delivery applications are provided alongside discus-
sion of their in vitro and in vivo evaluation. In particular, the discussions in 
this article will mainly focus on polymeric nanoparticles, hydrogels, inor-
ganic nanoparticles, and activatable prodrugs that have been integrated with 
diverse ROS-responsive moieties for spatiotemporally controlled release of 
drugs for effective therapy.
This is an open access article under the terms of the Creative Commons 
Attribution License, which permits use, distribution and reproduction in 
any medium, provided the original work is properly cited.
of ROS regulate cell signaling pathway 
and promote cell proliferation, whereas 
high levels of ROS induce the non-specific 
damage of proteins, lipids and DNA and 
kill the bacterial and pathogens.[2,3] There-
fore, a lack of ROS or an excess of ROS 
can induce the several diseases including 
autoimmune disease, cardiovascular dis-
ease, neurodegenerative disease and so 
on.[3,5–7] In particular, the increase of ROS 
levels is at risk for mutating the cellular 
DNA, which is closely linked to the pro-
gression of several cancer cells.[2,8–12]
This abnormal biochemical alteration in 
the disease sites has inspired researchers 
to exploit unbalanced ROS levels for 
developing target-specific drug delivery 
systems.[1] By utilizing ROS-responsive 
materials and linkers (Figure 1), various 
ROS-responsive drug delivery systems have been developed 
and investigated for the therapeutic purposes. Sometimes, 
photo sensitizers have been simultaneously utilized for syner-
gistic therapeutic efficacy, which are one of the representative 
exogenous ROS sources and have ability to excite oxygen to its 
singlet state by using exogenous light energy.[13–15]
The aim of this article is to provide an overview of current 
research activities that center on reactive oxygen species (ROS)-
responsive drug delivery systems. We discuss comprehensively 
design principle and in vitro/in vivo evaluation of various ROS-
responsive drug delivery systems, including polymer-based 
nanocarriers, hydrogels, inorganic nanoparticles-based sys-
tems, and activatable prodrugs. Finally, we conclude this review 
article with future perspectives on this area.
2. ROS-Triggered Drug Release from Polymeric 
Nanoparticles
Polymeric nanoparticles, formed through spontaneous self-
assembly of amphiphilic block copolymers, have been widely 
recognized as efficient carriers for delivery of wide range of 
imaging and therapeutic agents.[16–19] By controlling the hydro-
philic-lipophilic balance of block copolymers and the condition 
of solution state self-assembly, we can easily tune their physical 
properties such as morphology and size which greatly influence 
in vivo biodistribution. Their core–shell nano-sized structure 
enables polymeric nanoparticles to preferentially accumulate at 
the tumor site via enhanced permeation and retention (EPR) 
effect following systemic administration. It is also possible to 
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engineer their surface with targeting ligands for more efficient 
intracellular delivery via receptor-mediated endocytosis path-
ways. In addition to these targeting capabilities, integrating 
polymeric micelles with stimuli-responsive units holds great 
promise because it allow us to fine tune release characteristics 
of the loaded drugs in a spatiotemporally controlled fashion at 
the target site. Though several stimuli-responsive units that 
can respond to factors such as pH, temperature, light, enzyme 
or bioreducible environment have already been extensively 
explored in polymeric nanocarriers,[20–22] the incorporation 
of ROS-responsive units in polymeric nanoplatform for tun-
able drug release are only gaining attention very recently, as 
increasing evidence suggests that several pathogenic process 
are implicated with elevated ROS. In this section, we will sys-
tematically highlight the ROS-responsive polymeric micelles 
that have been developed thus far. The discussions in the fol-
lowing sections are organized according to the types of ROS-
responsive units incorporated in the polymeric nanoparticles.
2.1. Organochalcogen (Se or Te) and Organoborane-Based 
Linkers
2.1.1. Selenium
Selenium is an essential trace element for animals and humans 
and a member of the chalcogen family (group 16) on the peri-
odic table. It is also an important component of several vital 
enzymes such as glutathione peroxidase which plays significant 
role in protecting cells from oxidative damage. In particular, 
the lower bond energies of C-Se (244 kJ mol–1) and Se-Se 
(172 kJ mol–1) compared to the C-S (272 kJ mol–1) and S-S 
(240 kJ mol–1) make selenide or diselenide-containing polymers 
more sensitive under mild stimuli conditions than the sulfur 
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Figure 1. Representative ROS-responsive linkers that have employed for 
the design of ROS-responsive drug carriers.
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containing counterparts, which have inspired researchers to 
exploit the diselenide and monoselenide bond for developing 
stimuli-responsive drug delivery systems.
Zhang and co-workers first exploited the diselenide bonds 
for the development of ROS responsive micelles. They devel-
oped a triblock copolymer comprised of the poly(ethylene 
glycol)-b-polyurethane-b-poly(ethylene glycol) (PEG-PUSeSe-
PEG) which contains diselenide bonds in the hydrophobic 
polyurethane block. The developed polymers could form the 
micelles via self-assembly in water and facilitate the release 
of a model drug upon the glutathione (GSH) as well as H2O2 
stimuli (Figure 2A).[23] In addition, the further research demon-
strated that the micelles are also sensitive to even a low dose of 
γ-radiation, such as 5 Gy, which is close to the radiation dose for 
patients during a single radiotherapy treatment.[24] These results 
showed the potential applications in the combined radiotherapy 
and chemotherapy. The Xu groups developed light-responsive 
drug delivery systems by adopting the ROS-responsive behav-
iors of the PEG-PUSeSe-PEG micelles.[25] In order to control the 
drug release on demand, they encapsulated porphyrins, one of 
the photosensitizers, in the core of PEG-PUSeSe-PEG micelles. 
The 1O2 produced from the photosensitizer 
under red light irradiation facilitated the 
cleavage of the diselenide bonds, which led 
to the disruption of the micelles and release 
of doxorubicin (DOX). In spite of the ability 
to control the drug release, the therapeutic 
potential of ROS-responsive PEG-PUSeSe-
PEG micelles still needs to be investigated 
for the practical applications. Similarly, Wang 
groups developed light-responsive nanogel 
systems comprised of p(MAA-Se-Se-MAA) by 
copolymerizing N,N′-bis(methacryloyl) sele-
nocystamine (BMASC) and metharylic acid 
(MAA) (Figure 2B).[26] Indocyanine green 
(ICG) which has been approved by the US 
Food and Drug Administration (FDA) was 
employed to generate 1O2 for triggering the 
disassembly of diselenide-crosslinked nano-
gels on demand. Upon near-infrared (NIR) 
irradiation (785 nm), the enhanced DOX 
release and followed anticancer effects were 
demonstrated in vitro, which showed a poten-
tial in the use of targeted chemotherapy.
The hydrophobic monoselenide can be 
converted to the relatively hydrophilic sele-
noxide or selenone under oxidative condi-
tions. In order to examine the possibility of 
exploiting this unique characteristic of mono-
selenide for developing ROS-responsive drug 
delivery systems, Zhang and co-workers pre-
pared the PEG-PUSe-PEG copolymer which 
is similar to the PEG-PUSeSe-PEG, but 
contains monoselenide in the hydrophobic 
PU block (Figure 3A).[27] PEG-PUS-PEG 
copolymer was prepared as a control, which 
contains monosulfide in the hydrophobic PU 
block instead of monoselenide. The devel-
oped micelles were exposed to the mild oxi-
dative environment (0.1% H2O2 (v/v)) to investigate the ROS-
responsive structural disassembly. The thorough investigation 
including transmission electron microscope (TEM), Fourier 
transfer infrared (FT-IR), X-ray photoelectron spectroscopy 
(XPS) and nuclear magnetic resonance (NMR) demonstrated 
that the PEG-PUSe-PEG micelles are more sensitive to the oxi-
dant conditions compared to the PEG-PUS-PEG micelles owing 
to the high activity of selenide groups to the oxidants. Zhang 
and co-workers also developed amphiphilic block copolymers 
containing selenium in the side chain (PEO-b-PAA-Se) by 
conjugating 11-(benzylselanyl)undecan-1-ol to PAA of the 
poly(ethylene oxide-b-acrylic acid) (PEO-b-PAA).[28] Similar to 
the PEG-PUSe-PEG, the developed micelles was disassembled 
under the mild oxidative environment. More interestingly, the 
addition of Vitamin C which is one of the mild reductants led 
to the re-assembly of the micelles disassembled under ROS 
conditions, clearly indicating the high redox sensitivity of mon-
oselenide group. This characteristic has inspired researchers 
to develop several ROS-responsive drug delivery systems. 
Yan and co-workers reported selenium-containing (HBPSe) 
nano carriers for the efficient DOX delivery (Figure 3B).[29] The 
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Figure 2. A) Chemical structure of PEG-PUSeSe-PEG and schematic illustrations of self-assem-
bled micelles and their redox responsive disassembly. Reproduced with permission.[23] Copy-
right 2010, American Chemical Society. B) Illustration of preparation of diselenide-crosslinked 
nanogels and their NIR-regulated ROS-activated degradation, following on-demand controlled 
drug release. Reproduced with permission.[26]
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carriers were developed by biocompatible and biodegradable 
hyperbranched polymers composed of alternative phosphate 
segments and selenide groups in its backbone framework. The 
increased ROS levels of cancer cells facilitated the amphiphilic-
to-hydrophilic transition of the polymers, which led to the rapid 
disassembly of the nanoparticles. As a result, loaded DOX was 
released, which showed the enhanced apoptosis of cancer cells 
at in vitro level. In particular, it is important to note that the 
polymers can be degraded by enzyme digestion after the drug 
release, which has raised the expectations in the applications 
of the ROS-responsive drug delivery in practical cancer therapy.
2.1.2. Tellurium
Tellurium is another element of chalcogen family located below 
selenium in the periodic table. It is well known that electron-
egativity decreased as you go down a group, and therefore 
tellurium-based polymers are expected to possess a higher sen-
sitivity compared to that of selenium-based ones. In spite of this 
important advantage, tellurium-based polymers are still poorly 
explored for the design of ROS-responsive 
drug carriers. Only in recent studies, Xu 
and co-workers have synthesized two tellu-
rium-containing polymers with linear and 
branched architectures.[30,31] The linear Te-
containing amphiphilic copolymers (PEG-
PUTe-PEG) self-assembled into core–shell 
micelles in aqueous solution (Figure 4A). 
These micelles showed sharp swelling and 
concomitant increase in particle size not only 
when treated to physiologically relevant con-
centration of ROS (100 μM H2O2), but also 
when exposed to clinically relevant dose of 
γ-ray radiation (2 Gy) because ionizing radia-
tion is known to generate ROS by water radi-
olysis.[30] 1H NMR demonstrated that the 
swelling of micelles was mainly attributed to 
the disruption of the amphiphilicity via oxi-
dation of tellurium on the hydrophobic poly-
meric backbone to the higher oxidation states. 
The sharp ROS responsivity of tellurium-con-
taining micelles under the above two condi-
tions indicates that it might be a promising 
drug carrier for combination chemo and 
radio-therapies. Similar to linear polymers, 
the hyperbranched tellurium-containing poly-
mers (HBPTe) also formed nano-sized aggre-
gates and displayed ROS-responsive swelling 
(Figure 4B), which was greatly influenced by 
the degree of crosslinking of the polymer.[31] 
Because of the ability to incorporate a larger 
number of tellurium into the hyperbranched 
three dimensional structures, these nanoag-
gregates are proposed to find potential use as 
scavenging materials to eliminate excess ROS 
in applications such as antioxidant therapy. 
Although both of the aforementioned sys-
tems showed morphological changes in the 
presence of ROS, their cytotoxicity or potential as ROS-respon-
sive drug carriers have not been studied in detail with model or 
therapeutic drugs.
It has been demonstrated in previous study that the specific 
coordination chemistry between tellurium and platinum could 
enable effective loading of platinum-based anticancer drugs 
such as cisplatin and oxaliplatin into the micelles.[32] Therefore, 
the strategy utilizing the coordination chemistry between tellu-
rium and platinum would provide a novel route for developing 
ROS-responsive drug delivery systems although it has not been 
investigated.
2.1.3. Arylboronic Esters
In addition to their prominent function as important precur-
sors in organic synthesis, the arylboronic acid or arylboronic 
ester functional groups have also been extensively employed 
in the design of functional materials, in particular as sensors 
because of their intrinsic binding affinities to diols, amino alco-
hols, cyanide and fluoride. The specific interaction between 
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Figure 3. A) Schematic illustration of H2O2-responsive dissassembly of Se-containing block 
copolymer micelles. Reproduced with permission.[27] Copyright 2010, Royal Society of Chem-
istry. B) Schematic illustration for preparation of self-assembled nanoparticles from Se-
containing hyperbranched polymers and their intracellular drug release mediated by H2O2. 
Reproduced with permission.[29] Copyright 2013, American Chemical Society.
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arylboronic acid and glucose has prompted the researchers to 
synthesis arylboronic acid-based polymers and design glucose-
responsive polymer systems for controlled insulin delivery.[33] 
Similarly, in recent years, the oxidation of arylboronic esters 
to phenols and boronic acid with H2O2 has also received great 
attention to explore polymers bearing arylboronic esters as drug 
carriers for oxidation-responsive delivery.
An early effort in the utilization of arylboronic ester-based 
polymers as ROS-responsive drug delivery vehicles was made 
by Frechet and co-workers.[34] For this, they synthesized an 
oxidation-sensitive dextran (Oxi-DEX) derivative by conjugating 
hydroxyl groups of dextran with imidazoyl carbamate-activated 
phenyl boronic ester (Figure 5A). By employing this Oxi-Dex 
derivative, H2O2-responsive nanoparticles with size in the range 
of 100–200 nm were prepared using standard microemulsion 
method. Because of the solubility switch resulting from the oxi-
dation of arylboronic esters, these nanoparticles were quickly 
disassembled in phosphate buffer containing 1 mm H2O2, but 
they were stable in the absence of H2O2. As these nanoparticles 
were fabricated using biocompatible dextran as major constit-
uent, they were nontoxic to both HeLa human cervical epithe-
lial cells and RAW 264.7 murine macrophages. The potential 
of these nanoparticles as intracellular antigen delivery system 
for vaccine applications was investigated by loading chicken 
egg albumin (OVA). Interestingly, OVA-loaded Oxi-DEX 
nanoparticles showed significantly higher (by 27 fold) MHC I 
presentation as compared to the OVA-loaded oxidation-insen-
sitive conventional polymeric nanoparticles, indicating their 
high potential as ROS-responsive carriers for the delivery of 
hydrophilic biomacromolecular drugs. Zhang and co-workers 
developed another interesting ROS-triggered and regener-
ating anticancer nanosystem using an amphiphilic polymer 
(TBH), which was synthesized by conjugating D-α-tocopherol 
polyethylene glycol succinate (TPGS) to hyaluronic acid back-
bone via arylboronic ester linkage.[35] The amphiphilic conju-
gate formed self-assembled nanoparticles, in which anticancer 
drug DOX was effectively loaded by simple dialysis method. 
The DOX-loaded nanoparticles showed tumor cells-specific 
uptake in vitro via CD44-medidated endocytosis and disassem-
bled in the intracellular ROS environment through cleavage of 
arylbronic acid ester bond, which enabled to trigger the release 
TPGS and DOX (Figure 5B). The interaction of released TPGS 
with mitochondrial respiratory complex II induced further gen-
eration of ROS, which ensures complete dissociation of nano-
particles. Owing to P-glycoprotein (P-gp) inhibitory mechanism 
of TPG and high level of intracellular DOX concentration, the 
nanoparticles showed enhanced cytotoxicity in MCF-7/ADR 
cells. The nanoparticles demonstrated prolong in vivo circula-
tion in the blood and enhanced tumor targeting characteristics 
by combination of passive and active targeting mechanism. 
Further the nanoparticles showed excellent antitumor efficacy 
and a high survival rate in vivo as compared to free DOX and 
the control nanoparticles without arylboronic ester linkage.
In addition to the arylboronic ester-modified polysaccharide 
systems discussed above, synthetic copolymers incorporated 
with arylboronic ester units at the main backbone or side chains 
have also been synthesized and investigated as ROS-responsive 
drug carriers. For example, Almutairi and co-workers reported 
H2O2-responsive nanoparticles using two complementary poly-
mers bearing arylboronic ester groups, either linked directly or 
via an ether linkage to the main backbone (Figure 6A).[36] The 
nanoparticles were formulated via an oil/water emulsion tech-
nique. Upon exposed to physiologically relevant concentration 
of H2O2, the nanoparticles prepared using the polymer with 
an ether linkage showed much faster degradation compared 
to the other one (Figure 6B). Notably, these nanoparticles were 
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Figure 4. A) Chemical structure of linear amphiphilic tellurium-containing copolymers, and morphological changes of the respective micelles trig-
gered by H2O2 or 2 Gy γ-ray radiation. Reproduced with permission.[30] Copyright 2015, Royal Society of Chemistry. B) Preparation of self-assembled 
micelles from Te-containing hyperbranched polymers and their volume change by H2O2. Reproduced with permission.[31] Copyright 2015, Royal Society 
of Chemistry.
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completely degraded in activated neutrophils with high levels 
of ROS, and showed 2-fold enhancement of model drug release 
compared to the control poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles.
One of the problems associated with polymers bearing arylbo-
ronic esters is the generation of highly reactive quinone methide 
(QM) intermediates upon degradation. Under in vivo condi-
tions, these QMs can react with biomomolecules including pro-
teins and DNA, and induce harmful side effects. Further, QMs 
are also capable of depleting glutathione, a key intracellular 
antioxidant, leading to an altered redox balance within the cells. 
To address this issue, Li and co-workers designed nanoparticles 
using a new type of amphiphilic poly(amino ester)s containing 
pendant arylboronic ester units.[37] Upon H2O2-triggered degra-
dation of the nanoparticles, the built-in amino groups effectively 
quenched the generated QMs, thereby alleviating the biocom-
patibility concerns of the degradation products. Similarly, efforts 
have also been made to improve the polymer biocompatibility 
by constructing the arylboronic ester-based nanoplatforms using 
β-cyclodextrin (β-CD) which exhibits excellent biocompatibility 
and low immunogenicity as major a constituent of the carrier.[38]
Because of the complex biological envi-
ronment, in recent years, polymeric nano-
particles that have been integrated with mul-
tiple stimuli-sensitive units are being widely 
investigated because such systems enable to 
achieve desirable on demand drug release 
kinetics. In this regard, nanoparticles bearing 
an additional stimuli-sensitive unit along 
with ROS triggers have also been designed. 
For example Jia and co-workers synthesized 
two azomethine-based oligomers bearing 
arylboronate ester and imine moieties, as 
ROS- and pH-responsive units respectively, 
in the main chain through a condensation 
polymerization from a dialdehyde monomer 
containing a boronate group and an aro-
matic amine or an aliphatic amine.[39] The 
nanoparticles fabricated using these oli-
gomers were degraded either by oxidative 
conditions (H2O2) or acidic environment 
(low pH), leading to the release of payload 
in a controlled manner. In particular, the 
nanoparticles formed using oligomers with 
aliphatic amine showed a faster degradation 
rate in the presence of H2O2, especially in a 
weak acidic environment, as compared to the 
one made using aromatic amine. In another 
study, Li and co-workers synthesized inter-
esting oxidant/pH dual-responsive micelles 
using an amphiphilic block copolymers 
bearing pendant arylboronic ester and ortho 
ester groups (Figure 6C).[40] Upon oxida-
tion by H2O2, the arylboronic ester group 
within the micellar core rapidly oxidized to 
produce carboxylic acid, which subsequently 
improved the polarity of local microenviron-
ment of hydrophobic core and facilitated the 
uptake of water molecules, and accelerated 
the hydrolysis of ortho ester group. The degradation kinetics of 
the micelles was controlled by changing the polymer composi-
tion, concentration of H2O2 and pH condition. Notably, some 
of the micelles were extremely sensitive to the biorelevant con-
centration of H2O2 (50 μm). Considering the acidic conditions 
of tumor extracellular matrix and intracellular compartments 
of the cells such as endosomes and lysosomes, these ROS and 
pH-dual responsive carriers might have great potential for pre-
cise controlled release of anticancer therapeutics.
2.2. Sulfur-Containing Linkers
2.2.1. Thioether
As discussed above,[27] thioether group is similar to the mon-
oselenide group, which undergoes a phase transition from 
hydrophobic to hydrophilic under ROS conditions. Walker’s 
group explored the potential of thioether group in the develop-
ment of ROS-responsive drug delivery systems by preparing 
the nanoparticles composed of poly(propylene sulfide) (PPS) 
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Figure 5. A) Synthesis and H2O2-mediated degradation of Oxi-DEX. Reproduced with permis-
sion.[34] Copyright 2011, American Chemical Society. B) Schematic illustration of cellular uptake 
of regenerating anticancer nanosystem and proposed sub-cellular drug release. A: CD44-medi-
ated endocytosis, B: cleavage of arylboronate ester by ROS triggered disassembly and release 
of DOX and TPGS, C: upon its interaction with mitochondrial respiratory complex II, TPGS 
induced ROS generation for complete disassembly of nanosystem, D: TPGS acts as an effec-
tive P-gp inhibitor to hinder the efflux of DOX, E: DOX and ROS induced cell death in nucleus. 
Reproduced with permission.[35] Copyright 2014, Elsevier.
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containing thioether in its backbone.[41] They demonstrated 
that the oxidation of thioether in the PPS by the hypochlo-
rite led to the swelling of the nanoparticles. In particular, the 
ROS-generating enzymes such as chloroperoxidase (CPO) and 
human myeloperoxidase (hMPO) which generate HOCl at 
acidic pH induced the increased release of a model drug, which 
showed the practical potential of the thioether-mediated drug 
delivery systems. Li groups reported the oxidation-responsive 
drug delivery system by adopting the poly L-cystein derivatives 
(poly(L-EGxMA-C)n) containing thioethers in polypeptide side 
chains, which undergoes interesting structure transition under 
H2O2 conditions.[42] They found that the oxidation of thioether 
triggered the conformation change of poly(L-EGxMA-C)n from 
β-sheet to random coil. The increase of 
solubility as well as the structural changes 
have inspired the researchers to exploit 
poly(L-EGxMA-C)n as a hydrophobic block of 
the micellar systems. As a result, PEG45-b-
poly(L-EG2MA-C)22 micelle was prepared and 
showed the H2O2-responsive DOX release. 
These results have led to several researches 
to investigate the therapeutic potential of 
the delivery systems utilizing thioether 
linkers. Zhu and co-workers developed 
H2O2-responsive hyperbranced polymeric 
micelles for the delivery of 7-ethyl-10-hy-
droxy-camptothecin (SN38) and cinnamal-
dehyde (CA).[43] SN38 was conjugated to the 
hydrophilic hyperbranced polyglycerol (HPG) 
via ROS-responsive thioether linker and the 
CA which induces apoptotic cell death via 
ROS production was encapsulated in the 
resultant SN38-conjugated HPG micelles. 
The H2O2-responsive disassembly as well as 
drug release were demonstrated, which led to 
the efficient cytotoxicity on the several cancer 
cells including MCF-7, HeLa and HN-4. 
More importantly, the co-delivery of SN38 
and CA exhibited improved cell apoptosis 
compared to the single drug administration, 
which shows great potential of the strategy 
utilizing ROS-responsive linkers, ROS gen-
erating drugs and chemotherapeutic drugs. 
Recently, Lo et al. evaluated the potential of 
thioether-based ROS-responsive drug delivery 
systems at in vivo level (Figure 7).[44] They 
developed a dual redox responsive polymer 
composed of hydrophilic methoxy PEG and 
hydrophobic block response to H2O2 and 
GSH. The thioether and disulfide bonds 
were employed to impart the oxidation- and 
reduction-responsiveness, respectively. The 
micelles containing camptothecin (CPT) 
exhibited oxidation- and reduction-respon-
siveness and interestingly showed the cell-
dependent anticancer effects. In particular, 
the micelles induced efficient anticancer 
effects on the cancer cells compared to the 
free CPT although they showed the negligible 
cytotoxicity to the normal tissue cells which have low levels of 
ROS and GSH. Based on these results, the therapeutic potential 
of the dual responsive CPT delivery micelles was evaluated in 
HCT116 tumor-bearing mice. The micelles exhibited improved 
in vivo antitumor efficacy compared to the free drug, which 
open the possibility of the practical applications of thioether-
bearing drug delivery systems.
2.2.2. Thioketal
Thioketals are commonly used as carbonyl protecting group 
in organic synthesis because of their known stability to acidic 
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Figure 6. A) Chemical structures of polymers bearing arylboronic ester group linked directly (1) 
or via an ether group (2). B) Illustration of H2O2 mediated disassembly of nanoparticles formed 
using (2) and their degradation products. Reproduced with permission.[36] C) Illustration of dis-
assembly of oxidation and pH-dual responsive micelles bearing pendent arylboronic ester and 
ortho ester groups and their mechanism of disassociation (oxidation accelerated hydrolysis 
of ortho ester). Reproduced with permission.[40] Copyright 2013, American Chemical Society.
R
ev
ie
w
1600124 (8 of 19) wileyonlinelibrary.com © 2016 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
and basic conditions. However, thioketals can be cleaved 
through oxidative means. By taking advantage of this chem-
istry, Murthy and co-workers developed thioketal nanoparticles 
for oral delivery of siRNA to the inflamed intestinal tissues, 
which exhibit abnormally high levels of ROS.[45] The siRNA-
loaded nanoparticles were prepared by complexing siRNA 
with a cationic lipid (1,2-dioleoyl-3-trimethylammonium-
propane) followed by loading the resulting complexes into 
nanoparticles composed of ROS-responsive thioketal linkages 
incorporated polymer, poly(1,4-phenyleneacetonedimethylene 
thioketal) (PPADT). PPADT was readily synthesized using 
1,4-benzendimethanethiol and 2,2-dimethoxypropane via a 
step-growth polymerization method. As anticipated, these 
thioketal nanoparticles protected the complexes degrada-
tion in the harsh gastrointestinal tract fluids, but effectively 
unpacked the loaded siRNA at the sites of intestinal inflamma-
tion via ROS-mediated polymer degradation. Based on these 
results, PPADT nanoparticles were investigated as a carrier 
for small molecule anticancer drug paclitaxel (PTX).[46] Com-
pared to placebo PPADT nanoparticles, PTX-loaded PPADT 
nanoparticles demonstrated significantly high cytotoxicity in 
PC-3 prostate cancer cells which exhibit elevated levels of ROS 
compared to other cancer cells. This study demonstrated the 
feasibility of the development of targeted drug delivery using 
the ROS-responsive thioketal-based polymers. It should also 
be emphasized that thioketal-based ROS-responsive polymeric 
carriers are not widely explored as compared to others.
2.2.3. Vinyldithioether
Among various reactive oxygen species, 1O2 undergoes [2+2] 
cycloaddition with electron rich olefins such as vinyldith-
ioether to form unstable dioxetane intermediates, which 
spontaneously fragment to generate two carbonyl products. 
Based on this chemistry, Baugh et al. synthesized cleavable 
β-CD dimer as carrier of photosensitizer zinc phthalocyanine 
(ZnPc) for photodynamic therapy (PDT).[47] More recently, 
our group developed polymeric micelles based on biocompat-
ible poly(ethylene glocol)-b-poly(caprolactone) (PEG-b-PCL) 
copolymer bearing a 1O2-sensitive vinyldithioether linker at 
the core–shell junction for effective intracellular co-delivery 
of photosensitizer, chlorine e6 (Ce6), and anticancer drug, 
DOX (Figure 8).[48] Ce6 and DOX co-loaded micelles were pre-
pared using simple dialysis method. In vitro cell experiments 
using PC3 human prostate cell line revealed that these co-
loaded micelles under visible light irradiation more effectively 
released DOX inside the cells, and showed a higher anti-
tumor efficacy as compared to control micelles without the 
linker. This enhanced therapeutic efficacy was mainly attrib-
uted to the generation of 1O2 and the light-induced release 
of DOX upon 1O2-mediated cleavage of the vinyldithioether 
linker of the micelles. As light is an integral part of PDT, 
these micelles might have great potential for photo dyamically 
triggered drug release for effective combined chemotherapy 
and PDT.
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Figure 7. Chemical structure of oxidation and reduction-responsive block copolymer, and intracellular CPT release triggered by ROS and glutathione. 
Under high levels of H2O2 in cancer cells, the thioether linkers undergo hydrophobic-to-hydrophilic transition, which induces the swelling of the 
micelles. At the same time, the intracellular redox conditions trigger the clevage of disulfide bonds. These dual-responsive behaviors deformed the 
micelles, which induces the drug release. The graph represents in vivo tumor growth inhibition of CPT-loaded micelles. Reproduced with permission.[44] 
Copyright 2015, Elsevier.
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2.3. Other Linkers and Strategies
2.3.1. Aryloxalate
It has been well known that aryloxalates can easily react with 
oxidant H2O2 to form 1,2-dioxetanedione, which rapidly decom-
pose into carbon dioxide. Thus, strategically placing aryloxalate 
ester bond within the polymeric nanoparticles can induce their 
degradation and release the cargo upon exposing to H2O2.
Kang and co-workers developed H2O2-responsive p-hydroxy-
benzyl alcohol (HBA)-incorporated polyoxalate copolymer 
(HPOX) nanoparticles with strong antioxidant properties for 
therapeutic and diagnostic purposes (Figure 9A).[49,50] HBA is 
a major active pharmaceutical ingredient in Gastrodia elata, 
which has been widely used as herbal agents for the treatment 
of oxidative stress-related diseases. The copolymer was synthe-
sized by one-pot condensation reaction between oxalyl chloride, 
1,4-cyclohexanedimethanol and HBA. The HPOX nanoparticles 
were formulated by an oil-in-water emulsion method. The 
labile oxalate ester bonds on the copolymer can undergo com-
plete hydrolytic or H2O2-mediated degradation, which enables 
to release the active form of HBA to exert its therapeutic effect. 
In vitro evaluation of HPOX nanoparticles using LPS-activated 
RAW 264.7 cells demonstrated strong antioxidant and anti-
inflammatory activities by inhibiting the production of nitric 
oxide and reducing TNF-α.[49] The HPOX nanoparticles were 
also evaluated for H2O2 imaging and as targeted drug delivery 
vehicles for the treatment of ischemia-reperfusion injury.[50] In 
another study, a similar type H2O2-responsive antioxidant nan-
oparticle was fabricated by substituting the HBA with vanillyl 
alcohol (VA), another antioxidant. This polyoxalate copolymer 
bearing VA (PVAX) nanoparticle exhibited significant anti-
oxidant, anti-inflammatory and anti-apoptotic activities in both 
in vitro and in vivo models of ischemic/reperfusion injury.[51] 
Interestingly, PVAX nanoparticles prevented DOX-induced car-
diac dysfunction.[52] Taken the advantages of excellent biodegra-
dability, antioxidant property, and low cytotoxicity, these HPOX 
and PVAX nanoparticles have great potential as therapeutics for 
oxidative stress-associated disease.
To increase the sensitivity of the peroxalate-based nano-
particles, Wu et al. synthesized a dual sensitive ABA-type 
amphiphilic triblock polymer (PRDSP), wherein the middle 
hydrophobic block was incorporated with 
peroxalate ester units and disulfide bonds 
repeatedly, and PEGs were selected as outer 
hydrophilic blocks.[53] The DOX-loaded 
PRDSP nanoparticles showed accelerated 
release of DOX under biologically relevant 
concentration of glutathione (10 mm) and 
H2O2 (10 mm) compared to the physiological 
conditions (Figure 9B). Confocal laser scan-
ning microscopy and flow cytometric analysis 
showed effective delivery of DOX into the 
cytoplasm and nucleus of cells.
2.3.2. Ferrocene
Because of their unique redox properties, fer-
rocene-containing polymers are highly prom-
ising as a scaffold material for designing 
drug carriers, among several other applica-
tions.[54–56] As the ferrocene unit can be con-
verted from its hydrophobic neutral state to 
the hydrophilic charged species ferrocenium 
cation upon oxidation, the resulting hydro-
phobic-to-hydrophilic transition can be uti-
lized to trigger ROS-mediated drug release. 
For example, Zhang and co-workers synthe-
sized ferrocene-containing amphiphilic block 
copolymers poly(ethylene oxide)-b-poly(2-
formal-4-vinylphenyl ferrocenecarboxylate) 
(PEG-b-PMAEFc) via atom transfer radical 
polymerization.[57] In aqueous solution, this 
copolymer formed self-assembled vesicular 
nanostructures, but their morphologies can 
be effectively tuned by the factors such as pol-
ymer concentration, composition or addition 
of β-CD which is an appropriate host mol-
ecule that can form 1:1 inclusion complex 
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Figure 8. A) Chemical structure and B) Illustration of preparation of Ce6 and DOX co-loaded 
micelles and cellular uptake and visible light triggered 1O2-mediated intracellular co-delivery of 
DOX and Ce6 for combination chemo and photodynamic therapy. Reproduced with permis-
sion.[48] Copyrigh 2015, Royal Society of Chemistry.
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with ferrocene unit. The detailed investigation revealed that 
increasing the amount of β-CD induces a variety of intriguing 
structures, such as interconnected aggregates, compacted 
microstructures and large compound vesicles. The Rhoda-
mine B (RB)-loaded polymeric vesicles showed an accelerated 
release of RB in the presence of 1.4% H2O2, as compared to 
that one without any oxidant. It is also worth to mention here 
that reversible host-guest interactions between β-CD and fer-
rocene have also been exploited to construct voltage-responsive 
supramolecular vesicles for drug delivery applications.[55] Var-
ious ROS-responsive polymeric nanoparticles are summarized 
in Table 1. In general, these nanoparticles showed disassembly 
and concomitant drug release upon exposing to ROS, either 
through degradation of oxidation-labile linkers or hydrophilic-
to-hydrophobic transition.
2.3.3 Other Strategies
Gas-generating polymer nanoparticles are emerging as a poten-
tial carrier system for targeted triggered drug release.[58,59] In 
this system, the increase in internal pressure as a result of gas 
generated from the nanoparticles induces the disassembly of 
nanostructures and release of the loaded drugs. Thus, it does 
not necessarily demand the incorporation of stimuli-respon-
sive linkages within the polymeric nanostructures for drug 
release. The targeted triggered drug release from this system is 
accomplished by stimuli-controlled gas generation in response 
to specific microenvironmental changes associated with the 
diseases. By taking the advantages of O2-generation from the 
reaction between catalase and H2O2, Guo and co-workers pre-
pared an interesting carrier system that can generate O2 and 
deliver anticancer drugs in response to high H2O2 levels in 
the tumor microenvironment.[59] Biocompatible PLGA nano-
particles were chosen as the drug carrier, in which catalase and 
platinum-based drug as O2-generating agent and anticancer 
agent respectively, were loaded into aqueous core by double 
emulsion method. When these nanoparticles are taken up by 
the tumor cells, the O2 generated by the catalase from intracel-
lular H2O2 not only facilitates drug release but also be helpful 
in overcoming hypoxia-induced MDR which limits the effec-
tiveness of chemotherapy. Thus, the co-loaded nanoparticles 
demonstrated improved therapeutic efficacy against cisplatin 
resistant cell lines that are often appear to be in hypoxia. In 
a subsequent study, the authors investigated the potential of 
O2-generating nanoparticles for PDT against hypoxic cells 
(Figure 10A).[60] Although PDT that produces cytotoxic 1O2 by 
excitation of photo sensitizer with light of appropriate wave-
length in the presence of oxygen has become promising treat-
ment modality for several forms of cancers, the depletion of 
oxygen by photochemical consumption during PDT process 
and inherent tumor hypoxia of solid tumor significantly limit 
their successful clinical applications. Owing to O2-generating 
capacity at hypoxic conditions, it has been assumed that 
O2-generating nanoparticles might hold great promise to over-
come tumor hypoxia in PDT. To demonstrate this, c(RGDfK)-
functionalized PLGA nanoparticles loaded with photosensitizer 
methylene blue (MB) and catalase in the aqueous core, and 
black hole quencher-3 (BHQ-3) in the polymer shell, were pre-
pared. In the normal condition, BHQ-3 effectively quenched 
the 1O2 production of MB and mitigated the adverse off-target 
phototoxicity of nanoparticles until it reached the target cell. 
After selective uptake of the nanoparticles by αvβ3 integrin-rich 
tumor cells, H2O2 permeated into the core and was catalyzed by 
catalase to generate molecular O2, leading to the dissociation of 
the nanoparticles and release of MB (Figure 10B). The free de-
quenched MB under light irradiation induced the generation of 
1O2, which eventually destroyed the cancer cells. Overall, target 
specificity and H2O2-controlled and continuous O2-generating 
capability of these nanoparticles might be highly promising to 
improve PDT efficacy in hypoxic tumor.
3. ROS-Triggered Drug Release from Hydrogels
Hydrogels are three dimensional polymeric networks which 
generally have the capability to absorb large amounts of water 
or biological fluids.[61,62] These structures are mostly formed 
through crosslinking of hydrophilic polymer chains initiated 
by ionic, H-bonding, hydrophobic interactions or chemical 
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Figure 9. A) H2O2-activatable HPOX nanoparticles as imaging agents, 
therapeutics, and site-directed drug delivery systems for ischemia-reper-
fusion injury. Reproduced with permission.[50] Copyright 2013, Elsevier. 
B) Preparation of DOX-loaded PRDSP nanoparticles, their uptake and 
intracellular microenvironment triggered release of DOX. Reproduced 
with permission.[53] Copyright 2015, Royal Society of Chemistry.
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crosslinking. Because of their hydrophilicity and ability to 
mimic the extracellular matrix, hydrogels have become attrac-
tive biomaterials for the sustained and local delivery of thera-
peutic agents as well as supporting materials for cells during 
tissue regeneration. Among various hydrogels, injectable ones 
that can be formed in situ after being injected into the body 
offer high benefits over conventional preformed hydrogels 
because they can be administered via simple and minimally 
invasive procedure into the locations that are hardly acces-
sible via surgery.[63] Nevertheless, to harness the full potential 
of injectable hydrogels as a safe and effective drug delivery 
platform, it is also essential to impart specific drug releasing 
mechanism and in vivo biodegradability into them. The stim-
uli-responsive moieties have been widely employed to develop 
intelligent or smart hydrogels as they can change the hydro-
phobic/hydrophilic balance, entanglements of polymers and 
degree of crosslinking which are important in maintaining the 
structure of hydrogel.[64] Since various ROS-responsive units 
can cause hydrophobic to hydrophilic transition or polymer 
chain scission by degradation of the linkages under oxida-
tive environments, the incorporation of these ROS-responsive 
moieties into the hydrogel structures is expected to improve 
their resulting drug release characteristics. Therefore, in this 
section, we will discuss drug delivery hydrogels which undergo 
solubility switch or cleavage under high level of ROS.
3.1. Hydrogels with Solubility Switch Units
Duvall and co-workers demonstrated ROS-triggered drug release 
from thermoresponsive hydrogels which were prepared using a 
ABC type triblock copolymer, poly [(propylenesulfide)-b-(N,N-
dimethylacrylamide)-b-(N-isopropylacrylamide)] (PPS-b-PDMA-
b -PNIPAM) (Figure 11A).[65] At ambient temperature (25°C), 
this copolymer formed self-assembled micellar nanostructures 
with a hydrophilic PNIPAM corona and a hydrophobic PPS 
inner-core, which facilitated the loading of hydrophobic model 
drug Nile Red dye. When these assemblies were further heated 
to physiological temperature (37 °C), i.e., above low critical solu-
tion temperature (LCST) of PNIPAM, they transformed into 
stable hydrogels. As expected, upon exposing these hydrogels 
to H2O2, they showed a H2O2-concentration dependent release 
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Table 1. Polymeric nanoparticles that have been developed for ROS-triggered drug release.
Linkage Polymer Active agents or Model drug ROS-trigger Cell line References
Diselenide PEG-PUSeSe-PEG RB H2O2 (0.1–0.01%) or GSH (0.1–0.01 mg 
mL–1)
- [23]
  DOX γ-radiation (5 Gy) HepG2 [24]
 P(MAA-SeSe-MAA) DOX and ICG Light (600–780 nm)-induced ROS HeLa [26]
Monoselenide PEG-PUSe-PEG DOX H2O2 (0.1%) - [27]
 PEO-b-PAA-Se NR H2O2 (0.1%) - [28]
 HBPSe DOX H2O2 (0.1 mm) HeLa and NIH-3T3 [29]
Telluride PEG-PUTe-PEG - H2O2 (100 μm) γ-radiation (2 Gy) - [30]
 HBPTe - H2O2 (100 μm) - [31]
Arylboronic ester Oxi-Dex OVA H2O2 (1 mm) HeLa and RAW 264.7 [34]
 TBH DOX H2O2 (1 mm) MCF-7/ADR [35]
 P1 and P2 NR and FD H2O2 (50–100 μm) Raw264.7 and dMPRO [36]
 Azomethine-based oligomer NR H2O2 (10 mm) and/or H+ HeLa [39]
 Ortho-ester containing block 
copolymer
NR H2O2 (50 μm) - [40]
Thioether PPS NR and Reichardts dye NaOCl (25 ppm), CPO and hMPO with 
NaCl (200 mm) and H2O2 (500 μm)
- [41]
 Poly(L-EGx-MA-C)n DOX H2O2 (0.3%) - [42]
 HPG-2S-SN38 CA H2O2 (1–5 mm) HeLa, MCF-7 and HN-4 [43]
 mPEG-b-P(Des-alt-Cys) CPT H2O2 (1–100 μm) and GSH (1 μm–20 mm) HCT116 and L929 [44]
Thioketal PPAD TNF-α-siRNA KO2 RAW 264.7 [45]
  PTX KO2 (10 mm) or H2O2 (10 mm) PC-3 [46]
Vinyldithioether β-CD ZnPC Light-induced ROS - [47]
 PEG-b-PCL Ce6 and DOX Light (660 nm)-induced ROS PC-3 [48]
Aryloxalate HPOX HBA, 4-AN H2O2 (100 μm) RAW 264.7
[49]
 PVAX VA H2O2 (0.1 mm) C2C12 [51]
 PRDSP DOX H2O2 (10 mm) or GSH (10 mm) L929, A549 and HeLa [53]
Ferrocene PEG-b-PMAEFc RB H2O2 (1.4%) - [57]
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of Nile red due to the oxidative solubility switch of PPS block 
(Figure 11B). When subcutaneously injected in male BALB/c 
mice, the sustained release of dye lasted over 14 days from the 
hydrogels, but the diblock copolymer composition without the 
PNIPAM block quickly cleared from the injection site within 
1 day (Figure 11C), suggesting that thermo-responsive gelation 
is critical for local drug retention. These results indicate that 
these hydrogels have potential as H2O2-mediated on demand 
drug delivery system.
3.2. Hydrogels with Cleavable Units
Besides employing ROS-mediated solubility switch mecha-
nism, hydrogels integrated with ROS-responsive cleavable 
units have also been reported for controlled drug release. This 
type of hydrogel undergoes polymer scission under oxidation 
conditions as a major mechanism to trigger drug release. The 
release rate can be effectively tuned by controlling the degree 
of incorporated cleavable units. Furthermore, it also guarantees 
complete degradation of hydrogel polymeric compositions into 
non-toxic soluble molecules that can be excreted from the body, 
thereby evading unwanted immune response 
caused by prolong residence of the in situ 
formed gel.[63]
Based on a ROS-degradable diselenide-
containing block polymer and a peptide 
amphiphile as building blocks, Xu and 
co-workers fabricated a supramolecular 
hydrogel which can respond to oxidative 
species produced by γ-ray radiolysis of water 
(Figure 12A).[66] The hydrogel displayed a 
distinct gel-sol transition for a 0.5 kGy dose 
of radiation, while a hydrogel analogue pre-
pared with dynamic disulfide bonds using 
the same procedure failed to show any 
response even after exposed to a high dose 
of 5 kGy, indicating that gel–sol transition 
is proceed via cleavage of diselenide bond. 
As the peptide amphiphile is composed of 
a pain killer drug naproxen and a hexapep-
tide linked via photocleavable o-nitrobenzyl 
ester group, irradiation of the gels with UV 
light also induced gel–sol transition and trig-
gered the controlled release of naproxen. This 
result suggests that hydrogels made using 
diselenide-containing polymer could serve as 
potential carrier to deliver drugs with radia-
tion, especially for combination chemo and 
radiotherapy. By utilizing poly(NIPAM-co-
2-hydroxethyl acrylate) and ROS-cleavable 
diselenide-bearing crosslinking agents, Li 
et al. formulated oxidation and thermo-
responsive hydrogels for controlled delivery 
of salicyclic acid, a small molecular model 
drug (Figure 12B).[67] These hydrogels were 
prepared by coupling reaction between the 
pendant –OH group of the copolymer and –
NCO group of the crosslinker. The resulting 
gel networks quickly released the entrapped salicylic acid (over 
90 wt% in 24 h at 25 °C) when treated with an oxidizing agent 
H2O2, which could be due to the dissociation of the bulk gels via 
cleavage of diselenide bond into selenic acid. Also, the hydro-
gels showed thermo-induced drug release because its shrinkage 
promoted squeezing process above the LCST, but only 48 wt.% 
salicylic acid was release in 24 h at 40 °C. Although this study 
demonstrated preliminary oxidation-induced burst or thermo-
induced sustained drug release from the crosslinked hydrogels, 
it did not provide any in vitro or in vivo drug releasing experi-
ments mimicking physiologically relevant ROS conditions that 
are essential for real applications.
4. ROS-Triggered Drug Release from Inorganic 
Nanoparticles
Mesoporous silica nanoparticles (MSNs) are one of the widely 
exploited inorganic nanoparticles due to their favorable struc-
tural properties, such as easy preparation and functionalization, 
tunable particle size and pore size, and excellent biocompat-
ibility.[68–73] In addition, the pore-surface biphasic structure of 
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Figure 10. A). Schematic illustration of mechanism of H2O2-triggered release of photosen-
sitizer and O2 to accomplish PDT. B) Targeted intracellular generation of O2 and 1O2 by the 
nanoparticles for efficient PDT against hypoxic tumor cell. Reproduced with permission.[60] 
Copyright 2015, American Chemical Society.
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MSN allows not only to load various hydrophobic agents into 
their uniform mesoporous channel, but also to develop versatile 
drug delivery systems by endowing various functions including 
diagnosis, stimuli-responsiveness and targeting ability to the 
delivery systems. In particular, MSNs are 
known to induce the ROS generation in 
several cell lines, which show their poten-
tial in the development of ROS-responsive 
drug delivery systems.[74–80] Therefore, in 
this section, we would like to discuss the 
MSN-based ROS-responsive drug delivery 
systems.
4.1. Linker-Based System
One of the easiest ways to develop ROS-
responsive MSN drug delivery systems is 
to integrate ROS-responsive linkers within 
the nanostructure. Accordingly, our groups 
developed photoresponsive drug releasing 
systems (Pc@AP-E) based on MSNs by 
utilizing 1O2 sensitive linkers and 1O2-gen-
erating photosensitizers (Figure 13A).[81] 
ZnPc which generates 1O2 in response to 
long-wavelength light (ca. 600–700 nm) was 
loaded into the porous structure of MSNs via 
hydrophobic interactions, while 5-[(2-ami-
noethyl)amino]naphthalene-1-sulfonic acid, 
one of the model drugs, was decorated on 
the surfaces of MSNs via 1O2-labile vinyl-
dithioether linker. According to the design, 
light irradiation induced the 1O2 generation 
from the ZnPC in the pore of MSNs, which 
eventually facilitated the release of model 
drugs by cleaving the 1O2-sensitive linkers 
between MSNs and model drugs. Although 
this initial stage research demonstrated the potential use of 1O2 
as a trigger of on demand drug release systems using MSNs, 
their practical usefulness still needs to be verified in in vitro 
and in vivo systems.
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Figure 11. A) Chemical structure and illustration showing micelle gelation of PPS-b-PDMA-b-
PNIPAM and ROS-triggered release, B) H2O2-concentration dependent Nile red release, and 
C) time-dependent IVIS imaging of mice injected with diblock (green circle) and triblock copo-
lymer (blue circle). Reproduced with permission.[65] Copyright 2015, American Chemical Society.
Figure 12. A) Schematic illustration of formation of supramolecular hydrogel from diselenide-containing block copolymer and peptide amphiphile and 
γ-radiation induced degradation. Reproduced with permission.[66] B) Schematic illustration of formation of diselenide-crosslinked hydrogels, and their 
oxidation and thermo-responsive morphological change. Reproduced with permission.[67] Copyright 2015, Royal Society of Chemistry.
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4.2. Gatekeeper-Based System
There are several reports on the development of MSN-based 
ROS-responsive drug delivery systems without utilizing ROS-
responsive small molecule linkers. Zhu and Du groups sug-
gested a strategy utilizing metal nanoparticles as gatekeepers 
for ROS-responsive drug delivery, which is based on the ROS-
responsive stability of metal nanoparticles. They hypothesized 
that the ROS-responsive gatekeeper systems can be achieved 
if the metal nanoparticles that cap the pores of MSNs can be 
destabilized and removed from the MSNs by ROS. According 
to this logic, they employed the oxidative sensitive silver nano-
particles (Ag NPs) as gatekeepers to develop H2O2 sensitive 
drug delivery systems (Figure 13B).[82] Ibuprofen drug was 
loaded in the nanochannels of MSNs and the pores were capped 
by citrate passivated Ag NPs with ultrasmall size (4–6 nm) to 
prevent the premature release of drug. When exposed to H2O2, 
the outer citrate-stabilized surface of Ag NPs were etched and 
resultant destabilized Ag NPs immediately underwent the 
dissolution-accompanied aggregation. That is, H2O2 exposure 
led to the uncapping process of mesoporous nanochannels 
and subsequent release of drug molecules. As with the case of 
using Ag NPs, they reported hydroxyl radical (·OH) responsive 
gatekeeper systems (ZnS@CPT@MSNs) utilizing zinc sulfide 
quantum dots (ZnS QDs) as gatekeepers in another study.[83] 
Ultrasmall (3–4 nm in diameter) thiol stabilized ZnS QDs with 
free carboxylic acid groups was developed, followed by conju-
gating to amines groups in CPT-loaded MSNs to cap the 3 nm 
wide pores of MSNs. Because highly reactive ·OH which can 
be generated via Fenton reaction between H2O2 and Fe2+, the 
most abundant transition-metal in the body, induced destabili-
zation of thiol groups on ZnS QDs, the ZnS QDs were aggre-
gated and removed from the surface of MSNs. This process led 
to the release of CPT in controlled manner depending on the 
·OH. Because the system could be operated by the biorelavent 
concentrations of H2O2 and Fe2+, the developed ZnS@CPT@
MSNs exhibited high anticancer effects on BxPC-3 cells. In 
addition, the reduced cytotoxicity of ZnS@CPT@MSNs in the 
presence of antioxidant vitamin C suggested that the intracel-
lular ROS generation has an important role in the uncapping 
process and the release of CPT. Although the strategy utilizing 
metal nanoparticles as gatekeepers provides opportunity to 
avoid the use of ROS-sensitive linkers whose synthesis and 
modification are generally difficult, the cytotoxicity and the 
renal clearance issue of metal nanoparticles must be verified in 
in vivo systems for practical applications.
5. ROS-Activatable Prodrugs
In principle, prodrugs are inactive form of drug molecules that, 
following systemic administration, normally undergo enzy-
matic or chemical activation at the targeted site of the body to 
generate active parent drugs, which eventually elicit the desired 
pharmacological effects. The chief rationale behind the design 
of prodrugs is to improve the adverse properties of drugs such 
as poor solubility, lack of site specificity and inefficient cellular 
uptake. In fact, about 10% of globally marketed drugs are cat-
egorized as prodrugs, and this value is increasing as more drug 
developers utilize prodrug strategy to improve drug formula-
tions.[84–86] It is also interesting to note that approximately 20% 
of all new small molecular drugs approved between 2000 and 
2008 were prodrugs.[85] Indeed, many potent hydrophobic small 
molecule anticancer drugs have been successfully formulated 
as prodrugs to enable enhanced solubility and target specificity. 
Given the relatively high level of ROS in cancer cells, it is not 
surprising that ROS-activatable prodrugs could be one of the 
promising strategies for tumor-targeted therapy.[87]
A modular design of ROS-activatable prodrugs should 
encompass the following three functional domains: a ROS-
responsive trigger unit, an effector unit and a linker which joins 
both units together, as illustrated in Figure 14A. In these types 
of activatable prodrugs, once the trigger unit undergoes ROS-
mediated metabolism in tumor cells, the linker should rapidly 
transmits the trigger signal and activates the effector to cause 
significant cytotoxic effect. The earliest examples of ROS-acti-
vatable prodrugs have been designed mostly using arylboronic 
acid and their ester as a trigger unit.[88] Because of their well-
defined and facile chemistry for chemical modification, DNA-
alkylating agents have been initially investigated as effectors for 
ROS-activated prodrugs. For example, Peng et al. synthesized 
two H2O2-activatable anticancer prodrugs (Figure 14B) by con-
jugating DNA-alkylating nitrogen mustard with an arylboro-
nate and arylboronic acid.[89] Nitrogen mustards are one of the 
most useful DNA alkylating agents for cancer chemotherapy, 
but their applications are severely limited by lack of selectivity 
and toxicity. The as-synthesized prodrugs exhibited low tox-
icity under normal conditions because of the positive charge 
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Figure 13. A) Schematic illustration of the mechanism of drug release by 1O2 produced from light-activated photosensitizers. Reproduced with permis-
sion.[81] Copyright 2013, Royal Society of Chemistry. B) Schematic illustration of preparation of H2O2 responsive drug delivery systems utilizing Ag NPs 
as a gatekeeper. Reproduced with permission.[82] Copyright 2015, American Chemical Society.
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developed on the nitrogen mustard, which requires for alkyla-
tion. On the contrary, in the presence of H2O2, the prodrugs rap-
idly released nitrogen mustard mechloroethamine and caused 
significant cytotoxicity by facilitating DNA alkylation and cross-
linking formation. In vitro studies of the prodrugs also demon-
strated enhanced (60–90%) growth inhibition towards various 
cancer cells while the normal lymphocytes were less affected, 
indicating oxidative tumor specific activation of the nitrogen 
mustard is primary cause for effective cell killing. To enhance 
the cytotoxicity of H2O2-activatable prodrugs, in a subsequent 
study, an attempt has also been made by these authors through 
conjugation of the trigger unit with more than one effector.[90] 
The strategy utilizing arylboronic acid to develop H2O2-activable 
prodrugs was also exploited for the targeted cancer therapy by 
reversibly modulating protein function.[91] Xu groups modi-
fied lysine groups of cytotoxic protein ribonuclease A (RNase 
A) with 4-nitrophenyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)benzyl carbonate (NBC) to afford the RNase A-NBC capable 
of modulating its cytotoxicity in tumor environment. According 
to the design, the high level of H2O2 triggers the boronic acid 
initiated 1,6-elimination, which restores the activity of RNase 
A. The decreased isoelectric point (pI) of RNase A by boronic 
acid facilitated the electrostatic interactions with cationic lipid 
nanoparticles, which allowed the efficient intracellular delivery 
of the prodrug. Although the RNase A, RNase A-NBC, vacant 
lipid nanoparticles exhibited negligible cytotoxicity in vitro, the 
RNase A-NBC in lipid nanoparticles efficiently prohibited the 
growth of cancer cells. In particular, insignificant cytotoxicity 
was observed in noncancerous cells with low ROS levels, indi-
cating that the developed H2O2-responsive pro-protein has a 
potential in developing tumor selective anticancer therapeutics.
Another promising approach to improve effectiveness and 
the target selectivity of ROS-activatable prodrugs could be the 
strategy amplifying the intracellular ROS levels, because it 
not only increase the sensitivity of prodrug activation but also 
induce ROS-mediated cancer cell death depending on the levels 
and duration of ROS exposure.[2] Though cancer cells exhibit 
high oxidative stress with an increased production of ROS, 
they may not be able to survive above a certain threshold ROS 
levels. To ameliorate the adverse effects of heightened ROS, 
most cancer cells normally activate its ROS defense mecha-
nism, often through the upregulation of GSH or other antioxi-
dative molecules. Therefore, increasing the intracellular ROS 
by suppressing cellular antioxidant capacity and/or delivering 
exogenous ROS-generating agents could be a potentially useful 
strategy for selective killing of malignant cancer cells. Based 
on this logical premise, to simultaneously inhibit the antitoxi-
dative cellular system and induce generation of ROS, Mokhir 
group developed a H2O2-activatable prodrug by conjugating 
an aminoferrocene derivative to a pinacol boronate ester via a 
carbamate linker (Figure 14C).[92] In cancer cells with elevated 
ROS, this prodrug is able to generate an antioxidant QM and 
an aminoferrocene. The former one alkylates GSH, while 
the later one induces catalytic generation of hydroxyl radi-
cals. Thus, this dual effect may cause a strong oxidative stress 
in cells, thereby leading to cell death. When tested against 
Figure 14. A) Cartoon representing general molecular design of ROS-activatable prodrugs. B) Chemical structure of H2O2-activatable DNA alkylating 
nitrogen mustard prodrugs and their mechanism of action. Reproduced with permission.[89] Copyright 2011, American Chemical Society. C) Activation 
of ferrocene-based prodrug in the presence of H2O2. Reproduced with permission.[92] Copyright 2012, American Chemical Society. D) Intracellular 
activation of dual-stimuli-responsive prodrug. Reproduced with permission.[94] Copyright 2015, Nature Publishing Group.
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human promyelocytic leukemia cells (HL-60) and human 
glioblastoma-astrocytoma (U373), this prodrug showed potent 
cytotoxic effects with IC50 values of 9 μm and 25 μm, respec-
tively, which are largely attributed to their site-specific activa-
tion and expected synergistic action of the released products. 
The non-malignant cells such as fibroblasts were less affected 
by the prodrugs under practical conditions. However, at high 
concentrations (10 μm) and prolonged incubation times (72 h), 
the prodrugs can also be activated in normal cells which are 
known to exhibit low levels of ROS, indicating optimal dosage 
and time course is critical for future applications.[93] As a next 
step in this line of research, more recently, Lee and co-workers 
have synthesized an interesting dual stimuli (ROS and pH)-
responsive prodrug that can deliver QM and ROS-generating 
cinnamaldehyde (Figure 14D),[94] which is a major component 
of cinnamon that have been widely used as food additive and 
considered to be safe. It has been reported that CA can induce 
apoptosis through ROS generation primarily in the mitochon-
dria and inhibit growth of human cancer cells.[95] As mentioned 
above, since tumor microenvironment and cell organelles 
exhibit acidic characteristic, the additional pH-sensitive acetal 
linkage of the prodrugs may ensures effective release of the 
parent active agents for enhanced therapy. Based on the in vitro 
and in vivo studies performed using metastatic prostate cancer 
cells DU145, which are known to produce a large amount of 
ROS, they demonstrated this prodrug could produce syner-
gistic anticancer effect by suppressing antioxidant system and 
generating ROS. Nonetheless, further detailed studies on phar-
macokinetics and pharmacodynamics should be warranted to 
maximize its therapeutic potential.
As discussed in above sections, the integration of photosen-
sitizer into the ROS-responsive drug delivery systems facilitates 
the control of drug release on demand. The same rational was 
adopted by You groups to develop NIR-responsive ROS-acti-
vable prodrugs.[96] The prodrug is comprised of a phorphyrin 
derivative, a 1O2-responsive aminoarylate linker and a combret-
astatin A-4, a natural anticancer drug inhibiting tubulin poly-
merization. When NIR is irradiated to the prodrug, the phor-
phyrin generates the 1O2. This 1O2 induces the cleavage of the 
aminoarylate linker and subsequent release of active combret-
astatin A-4 drug. Notably, the developed drug not only showed 
the NIR-dependent anticancer effects in vitro, but also exhibited 
high therapeutic effects in vivo.
In recent years, activatable polymeric prodrugs (polyprod-
rugs), conjugation of active agents to polymers via biodegrad-
able spacers, have received enormous attention because of their 
merits such as improved water solubility, enhanced in vivo sta-
bility, prolonged half-life in blood, and specific tumor-targeting 
characteristic via active or passive targeting mechanism (EPR 
effect).[97,98] Further, it also provides an excellent opportunity 
to integrate imaging and therapeutic capability into a single 
platform, referred as theranostics which is emerging as a 
promising strategy in personalized medicine because, in addi-
tion to therapy, it also facilitates monitoring real-time localiza-
tion of drugs and assess in vivo therapeutic efficacy following 
treatment.[99–101] A representative example of ROS-activatable 
polyprodrug has been provided by Yuan et al., who chemi-
cally conjugated DOX molecules to a conjugated polyelectro-
lyte via ROS-cleavable dithioketal linkers (Figure 15A).[102] To 
impart solubility and targetability, they also conjugated hydro-
philic PEG and cyclic ariginine-glycine-aspartic acid tripeptide 
(cRGD) which target cancer cells overexpressed with αvβ3 inte-
grins respectively to the polyelectrolyte backbone. The conju-
gated polyelectrolyte not only exhibits bright fluorescence for 
cellular imaging but also acts as a photosensitizer to generate 
in situ ROS for triggered on demand DOX release and PDT 
under appropriate irradiation of light. By simple dialysis, the 
polyprodrug conjugates were formed into self-assembled nano-
particles (Figure 15B). Because of the combination of cRGD-
mediated targeting and white light-controlled ROS-triggered 
DOX-mediated chemotherapy and PDT, these self-assembled 
nanoparticles showed enhanced in vitro therapeutic activity on 
integrins αvβ3 overexpressed MDA-MBA-231 cells. In spite of 
these favorable results, it is also important to highlight here 
that the use of biomedically benign and high tissue penetrable 
NIR light rather than white light is indispensable to realize the 
full potential of this system for clinical settings.
6. Conclusion and Perspectives
The intracellular ROS levels have been arisen as an impor-
tant indicator for several diseases. Therefore, developing drug 
delivery systems which can respond to physiological relevant 
concentration of ROS have been significantly highlighted as 
a promising strategy in the field of drug delivery. Herein, we 
summarized and discussed the overall ROS-responsive drug 
delivery systems from prodrugs and nano-sized materials to 
macroscopic hydrogel. The successful development of ROS-
responsive drug delivery systems mostly depends on the 
availability of efficient ROS-responsive materials. The diverse 
ROS-responsive linkers discussed in this article trigger drug 
release from the carriers either by degradation or solubility 
switch (hydrophobic to hydrophilic) mechanism in response 
to ROS. The type of linker, sensitivity and its placement in 
the carrier system greatly influence the kinetics of the drug 
release. Each linker has its own advantages and limitations. For 
example, in spite of the high sensitivity of polymer containing 
organochalcogen (Se or Te)-based linkers, their cytotoxicity is 
a crucial factor that needs to be evaluated. Similarly, the gen-
eration of harmful QM upon degradation of arylboronic ester 
linkers remains as a significant concern. Thus, it is highly 
important to ensure that the degraded linkers are still biocom-
patible until they are completely cleared from the body as non-
toxic fragments.
Although numerous ROS-responsive drug delivery systems 
have been developed for biomedical applications, there are sev-
eral challenges to be addressed for practical applications. First, 
the safety of the materials in addition to the linkers needs to be 
considered primarily. The materials employed as the building 
block of carriers should be highly biocompatible, otherwise they 
may lead to unwanted inflammatory responses and thereby 
elevates ROS level, which could inadvertently affect the pro-
grammed drug releasing characteristics. Second, for the sys-
temically administered nanocarriers, the linkers incorporated 
in the carrier should be stable during circulation and at the 
normal cells with very low ROS levels, but effectively release 
the active agents after reaching at the pathological sites with 
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increased ROS levels. Third, since there are many variations in 
patients, disease conditions and the level of expression of ROS, 
the selection of linkers and the carrier design need to be inten-
sively considered for individual applications. Because of the 
complexity of the biological system, integrating other stimuli-
responsive moieties could be highly promising, and they could 
allow us to improve the therapeutic outcome by precise control 
of the carrier degradation and drug release rate. It is important 
to note that majority of ROS-responsive drug delivery systems 
have not been evaluated in vivo. The in vitro results do not 
always necessarily guarantee the in vivo efficacy. Furthermore, 
the selection of real oxidative environment for in vivo evalua-
tion also challenging, due to the rapid and dynamic changes in 
the ROS levels. Thus, efforts in integration of ROS-responsive 
drug delivery systems with the diagnostic agents, referred as 
theranostic systems, may also help to advance these systems for 
more precise drug delivery. Also, the low intrinsic ROS level in 
the tumor might also be disadvantage for real in vivo applica-
tion of ROS-responsive drug delivery system. Therefore, new 
studies that employ ROS-generating agents to increase tumoral 
ROS levels need to be explored. The ever-continued endeavor 
in circumventing aformentioned challenges is expected to 
allow to achieve the practical therapeutic applications of ROS- 
responsive drug delivery systems.
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